Get the Stockscreener App
7.10
0.85%
0.06
After Hours:
7.10
Precision Biosciences Inc stock is traded at $7.10, with a volume of 104.00K.
It is up +0.85% in the last 24 hours and up +17.94% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$7.04
Open:
$7
24h Volume:
104.00K
Relative Volume:
0.40
Market Cap:
$183.20M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.3705
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
-4.57%
1M Performance:
+17.94%
6M Performance:
-14.35%
1Y Performance:
+38.94%
1-Day Range:
$6.945
$7.24
1-Week Range:
$6.94
$7.975
52-Week Range:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.10 | 181.65M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences (DTIL) Presents Promising Data on PBGENE-D - GuruFocus
Gene-editing trial update points to fewer crises in 7 infants - Stock Titan
Precision BioSciences to present DMD gene therapy data at May conference - Investing.com
New Duchenne data backing earlier treatment gets ASGCT oral slot - Stock Titan
Should you buy Precision BioSciences (DTIL) after golden cross? - MSN
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4) - marketscreener.com
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Precision BioSciences (DTIL) Grants Inducement Award to New Empl - GuruFocus
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 - Business Wire
Empery Asset Management, LP Reduces Stake in Precision BioSciences Inc - GuruFocus
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences stock (US74019P1084): Is its gene-editing platform strong enough to unlock bio - AD HOC NEWS
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study - MSN
Precision BioSciences stock (US74019P1084): Is its gene editing platform strong enough to unlock bio - AD HOC NEWS
DTIL Assumed by Jones Trading -- Price Target Announced at $30 - GuruFocus
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 16.2% - MarketBeat
JonesTrading Reiterates Buy Rating for Precision BioSciences (NASDAQ:DTIL) - MarketBeat
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Jones Trading initiates Precision BioSciences stock coverage with buy rating - Investing.com UK
Jones Trading initiates Precision BioSciences stock coverage with buy rating By Investing.com - Investing.com South Africa
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences - European AIDS Treatment Group
Precision BioSciences Expands ELIMINATE-B Trial to Europe - National Today
Precision BioSciences (DTIL) Expands Hepatitis B Trial to Europe - GuruFocus
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries - BioSpace
Empery Asset Management, Ryan M. Lane (DTIL) disclose 7.63% ownership - Stock Titan
Precision BioSciences Expands Eliminate-B Trial for Pbgene-Hbv In France And Romania - marketscreener.com
Should You Buy Precision BioSciences (DTIL) After Golden Cross? - Yahoo Finance
DTIL Options Volatility — NASDAQ:DTIL - TradingView
DTIL Options Chain — NASDAQ:DTIL - TradingView
Jobs Data: How does Precision BioSciences Inc compare to its peersStock Surge & Verified High Yield Trade Plans - baoquankhu1.vn
How does Precision BioSciences Inc compare to its peersWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
DTIL Price Today: Precision BioSciences, Inc. Stock Price, Quote & Chart - MEXC
Precision BioSciences to Attend Healthcare Conference - National Today
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Precision BioSciences (NASDAQ: DTIL) details equity plan, charter change in 2026 proxy - Stock Titan
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Can PrecisionBio (DTIL) Stock Maintain Growth | Price at $6.14, Up 5.58%Pro Level Trade Signals - Xã Châu Thành
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):